Gilead signed a global deal for Genhouse Bio’s MAT2A‑targeting synthetic‑lethality asset GH31, paying $80 million upfront and structuring up to $1.45 billion in milestones plus tiered double‑digit royalties. GH31 has cleared IND reviews in China and the U.S. and is clinic‑ready, positioning Gilead to expand its oncology pipeline with a first‑in‑class approach. Gilead framed the acquisition as a disciplined bolt‑on to its oncology strategy, while Genhouse emphasized the transaction’s validation of its chemistry and synthetic‑lethality platform. The deal follows Gilead’s recent acquisitions of complementary precision oncology assets and signals continued biopharma appetite for external innovation via high‑value licensing and partnering. For the field, the GH31 transaction exemplifies pharma’s willingness to invest large milestone pools to secure novel cancer mechanisms with clinical readiness, and it highlights China‑origin innovation as increasingly competitive on a global scale.